| Patient Education |
|
Click here for patient education.
|
|
You are in: eMedicine Specialties >
Dermatology > DISEASES OF THE ADNEXA
Folliculitis
Article Last Updated: Apr 17, 2008
AUTHOR AND EDITOR INFORMATION
Section 1 of 11
Author: Elizabeth Kline Satter, MD, MPH, Staff Dermatologist and Head of Dermatopathology for Residency Program, Department of Dermatology, Naval Medical Center, San Diego
Elizabeth Kline Satter is a member of the following medical societies: Alpha Omega Alpha and American Medical Women's Association
Editors: Daniel J Hogan, MD, Director of Bay Pines Dermatology Residency Program, Bay Pines Veterans Affairs Healthcare System; Investigator, Hill Top Research, Florida Research Center; Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center; Paul Krusinski, MD, Director of Dermatology, Professor, Department of Internal Medicine, Fletcher Allen Health Care, University of Vermont; Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania; Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Author and Editor Disclosure
Synonyms and related keywords:
superficial folliculitis, deep folliculitis, infectious folliculitis, Staphylococcus aureus, Pseudomonas, gram-negative bacteria, herpes, dermatophytes, Pityrosporum, Demodex, perifolliculitis, impetigo of Bockhart, barbers itch, sty, sycosis barbae, sycosis barbae vulgaris, furuncle, carbuncle, acute generalized exanthematous pustulosis, tinea barbae, Majocchi granuloma, kerion, eosinophilic folliculitis, pseudofolliculitis barbae, shaving bumps, razor bumps, acne keloidalis nuchae
Background
Folliculitis is defined histologically as the presence of inflammatory cells within the wall and ostia of the hair follicle, creating a follicular-based pustule. The actual type of inflammatory cells can vary and may be dependent on the etiology of the folliculitis, the stage at which the biopsy specimen was obtained, or both. The inflammation can be either limited to the superficial aspect of the follicle with primary involvement of the infundibulum or the inflammation can affect both the superficial and deep aspect of the follicle. Deep folliculitis can eventuate from chronic lesions of superficial folliculitis or from lesions that are manipulated, and this may ultimately result in scarring.
Perifolliculitis, on the other hand, is defined as the presence of inflammatory cells in the perifollicular tissues and can involve the adjacent reticular dermis. Folliculitis and perifolliculitis can manifest independently or together as a result of follicular disruption and irritation.
Acne represents a noninfectious form of folliculitis. The follicular inflammation seen in acne occurs as a secondary event as a result of follicular obstruction from abnormal keratinization. In acne, the superficial aspect of the follicle distends and is obstructed by a keratin plug. The sebum fills the follicle, and the normally commensal bacteria (Propionibacterium acnes) produces excess free fatty acids, which trigger follicular inflammation. Of possible interest are eMedicine acne articles on acne, as follows:
Pathophysiology
Folliculitis is a primary inflammation of the hair follicle that occurs as a result of various infections, or it can be secondary to follicular trauma or occlusion.
Eosinophilic folliculitis differs in that it is thought to occur as a result of an autoimmune process directed against the sebocytes or some component of the sebum.
Although the etiology of papulopustular eruption secondary to epidermal growth factor receptor (EGF-R) inhibitors is unknown, it is hypothesized to occur secondary to abnormal epidermal differentiation that leads to follicular obstruction and subsequent inflammation.1, 2
Frequency
United States
Superficial folliculitis is common, but because it is often self-limited, patients rarely present to the doctor. Those who are seen more often have either recurrent/persistent superficial folliculitis or have deep folliculitis. Although the incidence is unknown, certain conditions make patients more susceptible. These include frequent shaving, immunosuppression, preexisting dermatoses, long-term antibiotic use, occlusive clothing and/or occlusive dressings, exposure to hot humid temperatures, diabetes mellitus, obesity, and use of EGF-R inhibitor medications.
Folliculitis has been reported following smallpox or anthrax vaccine. These cases may become more common because more military troops are being deployed.3
Mortality/Morbidity
Although complications are uncommon, they include cellulitis, furunculosis, scarring, and permanent hair loss.
Race
Folliculitis occurs in persons of any race, but pseudofolliculitis and traction folliculitis occurs more commonly in African Americans and classic eosinophilic folliculitis is more common in Japanese persons.4, 5
Sex
For most cases of folliculitis, no data are available to indicate the presence of a sexual predilection; however, eosinophilic folliculitis is reported to more frequently affect males and Pityrosporum folliculitis may have a slightly increased female incidence.
Age
Folliculitis can be seen in persons of all ages.
History
The patient typically reports an acute onset of papules and pustules associated with pruritus or mild discomfort.
Patients with deep folliculitis usually experience more pain and may have suppurative drainage. Persistent or recurrent lesions may result in scarring and permanent hair loss.
The papulopustular eruption secondary to EGF-R inhibitors typically occurs within the first 2 weeks of the initiation of therapy and can be associated with pruritus, pain, and desquamation.
Physical
Patients with superficial folliculitis usually present with multiple small papules and pustules on an erythematous base that are pierced by a central hair, although the hair may not always be visualized. Deeper lesions manifest as erythematous, often fluctuant, nodules. Sometimes, a patterned folliculitis occurs in areas that were shaved or occluded. Any hair-bearing site can be affected, but the sites most often involved are the face, scalp, thighs, axilla, and inguinal area.
Folliculitis has been traditionally divided into superficial and deep forms; however, most superficial forms can evolve into the deep form. The most common superficial form of infectious folliculitis is known as impetigo of Bockhart or barbers itch and is caused by Staphylococcus aureus. The lesions are seen in the bearded area, often on the upper lip near the nose, as erythematous follicular-based papules or pustules that may rupture and leave a yellow crust. The pustule is often pierced by a hair that is easily extracted from the follicle. This form of folliculitis occurs more commonly in carriers of nasal staphylococci. Another type of superficial folliculitis caused by staphylococci is a sty, which only differs from typical folliculitis in that it occurs on the eyelid. When involvement of the follicle is more extensive, a follicular-centered dermal abscess results. When the condition occurs on the face, it is referred to as sycosis barbae (vulgaris), but if it occurs elsewhere, it is referred to as a furuncle or boil. A confluence of several furuncles results in a carbuncle.6 Tinea barbae is an uncommon form of superficial folliculitis that clinically resembles its bacterial counterpart; however, it is caused by a superficial infection by various zoophilic dermatophytes. This superficial fungal folliculitis is most commonly seen in male farmers and typically affects one side of the face in the submaxillary region or chin. Patients with more extensive involvement of the follicle or those who experience an exaggerated hypersensitivity reaction to the dermatophyte infection present with enlarged, boggy purulent plaques, called kerions, in the site of the prior superficial infection. Another deep fungal folliculitis occurs on the legs of women who shave, and this is called Majocchi granuloma. See Tinea Barbae and Majocchi Granuloma. Gram-negative folliculitis primarily occurs in patients on long-term antibiotic therapy, often antibiotics given for the treatment of acne. This type of folliculitis arises from disequilibrium of the normal skin bacteria in favor of gram-negative organisms such as Enterobacter, Klebsiella, Escherichia, Serratia, and Proteus species. These lesions manifest as multiple small pustules that are most pronounced in the perinasal region and can spread to the chin and cheeks. See Gram-Negative Folliculitis. Pseudomonal folliculitis is another gram-negative folliculitis and is also known as hot tub (spa) folliculitis and wet suit folliculitis. It appears 8-48 hours after exposure to contaminated water or wet suits as erythematous follicular-based papules and pustules that are most concentrated in areas occluded by swimwear. This form of folliculitis may be associated with systemic findings such as fever, headache, sore throat, malaise, or gastrointestinal distress, but it is a self-limited condition that resolves in 7-14 days. Another similar condition is hot hand-foot syndrome, which occurs in a similar clinical situation but eventuates in painful erythematous nodules and papules on the palms and soles rather than folliculitis.7
Pityrosporum folliculitis is typically seen in young adults, with a slight female predominance, as intensively pruritic small uniform papules and pustules on the back, chest, and shoulders. It occurs more often in warm, humid climates and may be more frequent in immunocompromised patients or in patients on long-term antibiotics. This eruption is due to follicular infection by Malassezia furfur, which is a lipophilic yeast. An unusual cause of folliculitis occurs as a result of either overgrowth of Demodex mites or an acquired hypersensitivity to the mite. This form of folliculitis manifests with a more diffuse background erythema, in addition to the follicular-centered papules and pustules.8 An uncommon form of folliculitis is due to an infection with herpes viruses. This form of folliculitis can be caused by an infection by herpes simplex viruses 1 and 2 and is found in areas adjacent to a primary cold sore. It is spread by shaving. These lesions appear as grouped or scattered vesicles.9, 10 Varicella-zoster virus may also cause a primarily follicular-based infection. These patients present with erythematous plaques in a dermatomal distribution; however, vesicles do not typically occur. Biopsy is often required to confirm the diagnosis.10 Folliculitis can also have a noninfectious etiology caused by follicular trauma or occlusion or may simply be idiopathic. For example, pseudofolliculitis barbae, also known as shaving or razor bumps, occurs primarily in the bearded area of African American males or other racial groups with thick, coarse, curly hair. This condition is not a folliculitis per se, but rather a perifolliculitis that arises as a result of the hair reentering the skin adjacent to its exit point from the follicle. The hair then acts as a foreign body and incites inflammation. The inflammation can spontaneously resolve if the hair is extracted or it can become associated with a chronic foreign body granulomatous reaction and may result in scarring. See Pseudofolliculitis of the Beard. Acne keloidalis nuchae is a similar condition that arises on the neck and occipital region of the scalp, but this condition is both a folliculitis and perifolliculitis and has greater potential for scarring. See Acne Keloidalis Nuchae. Acute generalized exanthematous pustulosis and anticonvulsant hypersensitivity syndrome both manifest as an acute onset of a discrete pustular eruption arising shortly after beginning therapy with various medications. Although the eruption that occurs in acute generalized exanthematous pustulosis is often differentiated from anticonvulsant hypersensitivity syndrome by having nonfollicular-based pustules, either condition can have follicular or nonfollicular-based pustules. Papulopustular drug eruption due to EGF-R is a relatively new entity and consists of a follicular eruption on the face, chest, and upper back that occurs approximately 2 weeks after initiation of chemotherapy. It is seen in up to 90% of patients taking EGF-R inhibitors, and its presence correlates to a positive response to chemotherapy.1, 2
The last noninfectious folliculitis to be discussed is eosinophilic folliculitis. It manifests as intensely pruritic pustules and can occur in at least 3 different clinical situations. The first is the original description of eosinophilic folliculitis, also know as Ofuji disease. It arises in Japanese males at an average age of 30 years. The lesions initially begin as discrete papules and pustules that eventually coalesce to form circinate plaques composed of a peripheral rim of pustules with central clearing. These lesions appear cyclically on the face, back, and extensor surfaces of the arms and spontaneously resolve in 7-10 days. Often, peripheral eosinophilia is present.5 A second form of eosinophilic folliculitis arises in patients with AIDS and other conditions that result in immunosuppression. This form is seen most often in adult males with a CD4+ count of less than 300 cells/μL. It is persistent and does not form an annular pattern. The lesions tend to favor the face, scalp, and upper trunk.11 The last form of eosinophilic folliculitis occurs in infants, usually within the first 24 hours to first few weeks of life. It is more common in male infants and usually is self-limited; however, as in Ofuji disease, it may follow a cyclic course lasting months to years. The lesions primarily affect the scalp and eyebrows. This form may also be associated with peripheral eosinophilia.
Causes
The causes of folliculitis are multiple and include infection, friction and other causes of follicular trauma, excessive perspiration, and occlusion; however, many cases remain idiopathic. Patients who have a reduced immune status, prior skin injury, or dermatoses or those who are obese may be more at risk.
Acne Vulgaris
Acneiform Eruptions
Candidiasis, Cutaneous
Coccidioidomycosis
Contact Dermatitis, Irritant
Dermatologic Manifestations of Renal Disease
Erythema Toxicum Neonatorum
Fire Ant Bites
Fox-Fordyce Disease
Graham-Little-Piccardi-Lasseur Syndrome
Id Reaction (Autoeczematization)
Impetigo
Insect Bites
Milia
Miliaria
Papular Urticaria
Perioral Dermatitis
Pruritic papular eruption of HIV disease
Rosacea
Seabather's Eruption
Subcorneal Pustular Dermatosis
Lab Studies
Laboratory studies are typically not obtained because diagnosis is usually made based on history and physical examination findings alone. In cases resistant to standard therapy, cultures, Gram stain, potassium chloride (KOH) preparation, and biopsy are the diagnostic tests of choice. - Gram stain and bacterial culture are best performed by unroofing an entire pustule with a No. 15 blade and depositing material onto a glass slide and a sterile cotton swab. In typical cases, Gram stain shows gram-positive cocci, and culture grows S aureus. Pseudomonas species can be cultured from the pustules of hot tub folliculitis.
- Nasal culture of family members to look for S aureus colonization may be needed in chronic cases.
- KOH inspection, fungal culture, or both can be useful for diagnosing dermatophyte infections. Pityrosporum yeast forms are best appreciated on biopsy specimens in cases of Pityrosporum folliculitis
- Viral culture or biopsy assists in the identification of folliculitis caused by herpes simplex virus.
- A small punch biopsy (3-4 mm) of an active lesion should be performed in atypical cases or in patients resistant to standard treatments. Patients with eosinophilic folliculitis show eosinophils and lymphocytes within the hair follicle. A complete blood cell count often reveals leukocytosis and eosinophilia, with an elevated immunoglobulin E level.
Procedures
For deep infections, incision and drainage can be therapeutic and can provide material to be sent for culture.
Histologic Findings
Histologically, all cases of superficial folliculitis have a similar appearance in that they show a moderately intense infiltrate of inflammatory cells in the follicular ostium and upper regions of the follicle. In most cases, the inflammation initially consists of neutrophils and then becomes more mixed with the addition of lymphocytes and macrophages. If the folliculitis is from an infectious cause, then various organisms can be identified within the follicle.12
Folliculitis can also extend deeper, with the inflammation involving the entire length of the follicle and often encompassing the adjacent dermis as a focal dermal abscess. In perifolliculitis, the inflammation is restricted to the area immediately surrounding the follicle.
The histopathological evaluation of herpes folliculitis can be subtle and nonspecific and often requires that deeper histological sections are obtained in order to see the characteristic histological changes. Typically, a dense lymphohistiocytic infiltrate is noted, often admixed with neutrophils that surround and frequently destroy the hair follicle. The characteristic changes of a herpes infection, namely balloon degeneration of the keratinocytes of the follicle, scattered multinucleated cells, and keratinocytes with enlarged gray nuclei that have peripheral margination of the chromatin, are seen in approximately half the cases on which a biopsy has been performed. Most cases of herpes folliculitis have been shown to be caused by a varicella-zoster infection, and, initially, the infection is centered on the sebaceous gland.9
In pseudofolliculitis barbae and acne keloidalis nuchae, the inflammatory infiltrate is initially perifollicular and is composed of neutrophils and lymphocytes; however, later, they are replaced by monocytes and plasma cells. Often, free hair shafts without the accompanying follicle can be identified within the dermis. The hair shafts are typically surrounded by acute or granulomatous inflammation and fibrosis. Hypertrophic scar is often present.12
The histological features of eosinophilic folliculitis include a collection of eosinophils within the superficial follicle associated with eosinophilic spongiosis and a mild perifolliculitis. This type of folliculitis is often associated with follicular mucinosis.5
The histological features of a papulopustular eruption due to EGF-R inhibitors is that of a superficial purulent folliculitis, which, in most cases, is sterile but can occasionally be associated with S aureus infection.2
Medical Care
For recurrent uncomplicated superficial folliculitis, use of antibacterial soaps and good hand washing technique may be all that is needed. For refractory or deep lesions that have a suspected infectious etiology, empiric treatment with topical and/or oral antibiotics that cover gram-positive organisms may be of benefit. If a patient does not improve with a standard course of antibiotics, other causes of folliculitis must be investigated. If systemic antibiotics are indicated, coverage should include S aureus, because S aureus is the most common pathogen. This organism often is penicillin resistant; therefore, dicloxacillin or a cephalosporin is the first choice. Methicillin-resistant organisms are becoming more common, and treatment may require clindamycin, trimethoprim-sulfamethoxazole, minocycline, or linezolid. For recurrent and recalcitrant folliculitis, mupirocin ointment in the nasal vestibule twice a day for 5 days may eliminate the S aureus carrier state. Family members also may be nasal carriers of S aureus, and mupirocin ointment or rifampin at 600 mg/d orally for 10 days may eliminate the carrier state. Medical care for the other types of folliculitis is as follows: - Pseudomonas folliculitis is usually self-limited and does not require treatment; however, if the patient is immunocompromised or the lesions are persistent, oral ciprofloxacin may be given.
- Eosinophilic pustular folliculitis does not respond to systemic antibiotics; however, it may respond to isotretinoin, metronidazole, UV-B phototherapy, indomethacin, or itraconazole.
- Pityrosporum folliculitis initially responds to topical antifungals such as ketoconazole cream or shampoo but is often associated with relapses. For relapses, systemic antifungals should be tried.
- Herpetic folliculitis responds to valacyclovir, famciclovir, or acyclovir.
- Papulopustular eruption associated with EGF-R inhibitors is self-limited and resolves with cessation of chemotherapy. In patients requiring treatment, topical antibiotics or topical corticosteroids can be used, and, in recalcitrant cases, oral antibiotics can be administered.
Consultations
The patient's primary care provider can usually diagnose and treat uncomplicated cases of folliculitis, but for those cases that are persistent or result in scarring, a dermatologist should be consulted.
Diet
Because folliculitis is more common in individuals who are obese, weight reduction may be helpful.
Activity
If the patient equates episodes of folliculitis to wearing a wet suit or other sports gear, these items should be cleaned with antimicrobial soaps and dried well.
Topical antibiotics can be used as first-line agents in cases of recurrent superficial folliculitis. If the area involved is widespread or persistent or if a deep infection is present, systemic antibiotics may be indicated. The drug of choice must cover penicillin- or methicillin-resistant S aureus in areas of high prevalence or in predisposed patients.
Drug Category: Antibiotics
For patients who do not respond to standard antimicrobial treatments, therapy should be guided by culture sensitivity.
| Drug Name | Erythromycin, topical (Erycette) |
| Description | Topical solution (2%). Indicated for infections caused by susceptible strains of microorganisms. |
| Adult Dose | Apply to affected area bid until clear |
| Pediatric Dose | Apply as in adults |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | Prolonged or repeated antibiotic therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms and may lead to a secondary infection (take appropriate measures if superinfection occurs) Pseudomembranous colitis may occur after use of systemic antibiotics or, rarely, topical preparations; therefore, temporarily discontinuing antibiotics in patients who develop diarrhea is prudent
|
| Drug Name | Clindamycin, topical (Cleocin T) |
| Description | Topical solution. Lincosamide for treatment of serious skin and soft tissue staphylococcal infections. Also effective against aerobic and anaerobic streptococci (except enterococci). Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest. |
| Adult Dose | Apply to affected area bid |
| Pediatric Dose | Apply as in adults |
| Contraindications | Documented hypersensitivity; regional enteritis, ulcerative colitis, hepatic impairment, and antibiotic-associated colitis |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | Prolonged use may result in overgrowth of nonsusceptible organisms (eg, fungi); discontinue use if superinfection occurs |
| Drug Name | Mupirocin (Bactroban) |
| Description | DOC for localized disease; inhibits bacterial growth by inhibiting RNA and protein synthesis. |
| Adult Dose | Ointment: Apply on affected area tid |
| Pediatric Dose | Apply as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | Prolonged use may result in growth of nonsusceptible organisms; use with caution over large surface areas, especially in the setting of moderate-to-severe renal disease, owing to polyethylene glycol absorption, which is excreted by the kidneys |
| Drug Name | Cephalexin (Keftab) |
| Description | First-generation cephalosporin that arrests bacterial growth by inhibiting bacterial cell wall synthesis. Has bactericidal activity against rapidly growing organisms. Has primary activity against skin flora; used for skin infections or prophylaxis in minor procedures. Although cephalosporins have significant staphylococcal coverage in most populations, coverage of Pasteurella species is not as good as amoxicillin and clavulanate. |
| Adult Dose | 1-4 g/d PO divided bid/qid for 10-14 d |
| Pediatric Dose | Mild-to-moderate infection of skin and/or subcutaneous tissue: 25-50 mg/kg/d PO divided q6h, not to exceed 4 g/d, depending on type and severity of infection Severe infection of skin and/or subcutaneous tissue: 50-100 mg/kg/d PO divided q6h, depending on type and severity of infection
|
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with aminoglycosides increases nephrotoxic potential; cholestyramine may decrease absorption; may increase metformin toxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy; caution in patients with GI disease (particularly colitis); may result in false-positive reaction for urine glucose using copper-reduction method (eg, Clinitest, Benedict solution, Fehling solution); use urine glucose tests based on enzymatic glucose oxidase reactions (eg, Clinistix, or Tes-Tape) in patients receiving cephalexin therapy |
| Drug Name | Dicloxacillin (Dynapen) |
| Description | Treatment of infections caused by penicillinase-producing staphylococci. May use to initiate therapy when staphylococcal infection is suspected. |
| Adult Dose | 125-500 mg PO q6h for 10-14 d |
| Pediatric Dose | Neonates: 4-8 mg/kg PO q6h <40 kg: 12.5-50 mg/kg/d PO divided q6h >40 kg: 125-500 mg PO q6h
|
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effect of penicillins; tetracyclines may decrease effect of penicillins with concurrent use; concomitant penicillin and aminoglycoside therapy has been reported to result in inactivation of the aminoglycoside both in vivo and in vitro; penicillins may alter intestinal flora which, in turn, alters the enterohepatic circulation of combination contraceptives; may reduce the anticoagulant effectiveness of warfarin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | Caution in impaired renal function |
| Drug Name | Erythromycin (Ery-Tab, E-Mycin, Eryc) |
| Description | Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections. In children, age, weight, and severity of infection determine proper dosage. When bid dosing is desired, half-total daily dose may be administered q12h. For more severe infections, dose is doubled. |
| Adult Dose | 250 mg erythromycin stearate/base qid PO 1 h ac or 500 mg PO bid; alternatively, 333 mg PO q8h for 10-14 d |
| Pediatric Dose | 30-50 mg/kg/d PO divided q6-8h |
| Contraindications | Documented hypersensitivity; hepatic impairment; concomitant administration with cisapride |
| Interactions | May significantly alter metabolism of nonsedating antihistamines and cause serious adverse cardiovascular events; concurrent use of lovastatin and erythromycin may cause rhabdomyolysis in patients who are seriously ill; may increase serum theophylline levels and toxicity; concomitant administration of digoxin may result in elevated serum digoxin levels; coadministration can increase effects of anticoagulants; concurrent use with ergotamine or dihydroergotamine has been associated with acute ergot toxicity; erythromycin may decrease clearance of triazolam and midazolam; erythromycin in patients taking other drugs metabolized by cytochrome P-450 system may be associated with elevations in serum concentrations of those drugs; has demonstrated QTc prolongation in combination with other drugs that prolong the QT interval |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; adverse GI tract effects are common (administer doses pc); discontinue if nausea, vomiting, malaise, abdominal colic, or fever occur; elderly patients may experience increased susceptibility to torsades de pointes arrhythmias |
| Drug Name | Clindamycin (Cleocin) |
| Description | Lincosamide for treatment of serious skin and soft tissue staphylococcal infections. Also effective against aerobic and anaerobic streptococci (except enterococci). Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes causing RNA-dependent protein synthesis to arrest. |
| Adult Dose | 150-450 mg PO q6-8h for 10-14 d |
| Pediatric Dose | 10-30 mg/kg/d PO divided q6-8h |
| Contraindications | Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin; cyclosporine levels may decrease when administered concurrently; kaolin may reduce absorption |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | Adjust dose in severe hepatic dysfunction, no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis; may result in colitis; occasionally results in overgrowth of nonsusceptible organisms (eg, yeast) |
| Drug Name | Minocycline (Minocin) |
| Description | Not DOC for staphylococcal infection. Treats infections caused by susceptible gram-negative and gram-positive organisms, in addition to infections caused by susceptible Chlamydia, Rickettsia, and Mycoplasma species. Was found to be effective in some nontuberculotic mycobacterial infections. |
| Adult Dose | 100 mg PO q12h for 10-14 d |
| Pediatric Dose | 2 mg/kg PO q12h |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of PO contraceptives, causing breakthrough bleeding and increased risk of pregnancy; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; concomitant use of vitamin A supplementation or oral retinoids (eg, isotretinoin) not recommended; additive risk of pseudotumor cerebri; simultaneous administration of cinnamon and tetracycline may slow tetracycline absorption; bacteriostatic drugs (eg, tetracyclines) may interfere with bactericidal effect of penicillin |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
|
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines; hepatitis or lupuslike syndromes may occur; autoimmune syndromes; drug-induced lupus–like syndrome, hepatitis, and vasculitis reported with long-term use; caution in preexisting renal impairment; risk of azotemia, hyperphosphatemia, and acidosis due to drug accumulation; minocycline use may result in false elevations of urinary catecholamine levels due to interference with the fluorescence test |
| Drug Name | Rifampin (Rifadin) |
| Description | For use in combination with at least 1 other anti-TB drug. Inhibits DNA-dependent bacterial RNA polymerase but not mammalian RNA polymerase. Cross-resistance may occur. Treat for 6-9 mo or until 6 mo have elapsed from conversion to sputum culture negativity. |
| Adult Dose | 600 mg/d PO for 10 d |
| Pediatric Dose | 20 mg/kg/d PO divided q12h for 10 d |
| Contraindications | Documented hypersensitivity |
| Interactions | Induces microsomal enzymes (especially P450 CYP3A4-mediated metabolism), which may decrease effects of acetaminophen, oral anticoagulants, barbiturates, benzodiazepines, beta-blockers, chloramphenicol, oral contraceptives, corticosteroids, mexiletine, cyclosporine, digitoxin, disopyramide, estrogens, hydantoins, methadone, clofibrate, quinidine, dapsone, tazobactam, sulfonylureas, theophyllines, tocainide, digoxin, and other medications metabolized by this system; blood pressure may increase with coadministration of enalapril; coadministration with isoniazid may result in higher rate of hepatotoxicity than with either agent alone (discontinue 1 or both agents if alterations in LFTs occur) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | Obtain CBC counts and baseline clinical chemistries prior to and throughout therapy; in liver disease, weigh benefits against risk of further liver damage; interruption of therapy and high-dose intermittent therapy are associated with thrombocytopenia that is reversible if therapy is discontinued as soon as purpura occurs; if treatment is continued or resumed after appearance of purpura, cerebral hemorrhage or death may occur |
| Drug Name | Ciprofloxacin (Cipro) |
| Description | Inhibits DNA gyrase and topoisomerase IV for bactericidal activity. Use as an alternative for MRSA infection. |
| Adult Dose | 250-750 mg PO q12h for 10-14 d |
| Pediatric Dose | 20-30 mg/kg/24 h divided dose q12h; not to exceed 1.5 g/24 h |
| Contraindications | Documented hypersensitivity |
| Interactions | Inhibits hepatic metabolism (monitor levels of clozapine, warfarin, and theophylline); can lead to increased caffeine levels; probenecid decreases excretion |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | Decrease dose in patients with renal dysfunction; rapid infusions may cause hypotension; fluoroquinolones cause arthropathy and osteochondrosis in juvenile animal lab studies (not routinely recommended or used in children <18 y without extreme caution); photosensitivity and seizures (latter especially if also taking NSAIDs) have occurred with this class of medication Interacts with oral hypoglycemic agents; avoid coadministration with QT-prolonging agents (including class Ia and III antiarrhythmics, erythromycin, cisapride, antipsychotics, and cyclic antidepressants); avoid taking with antacids, zinc, iron, didanosine, or sucralfate; adverse neurologic effects reported (eg, dizziness); musculoskeletal problems (eg, tendinitis, tendon rupture); patient should stay well hydrated |
Drug Category: Antifungal agents
Many topical antifungal preparations are available to treat the forms of folliculitis (eg, tinea barbae, Pityrosporum folliculitis) caused by fungus. Topical agents should be active against dermatophytes.
| Drug Name | Ketoconazole (Nizoral) |
| Description | Imidazole broad-spectrum antifungal agent. Inhibits synthesis of ergosterol, causing cellular components to leak, resulting in fungal death. |
| Adult Dose | Topical: Apply thin film bid for 2 wk Systemic: 200-400 mg/d PO
|
| Pediatric Dose | Topical: Apply as in adults Systemic <2 years: Not established >2 years: 3.3-6.6 mg/kg/d PO once
|
| Contraindications | Documented hypersensitivity; fungal meningitis |
| Interactions | Isoniazid may decrease bioavailability; coadministration decreases effects of either rifampin or ketoconazole; may increase effect of anticoagulants; may increase toxicity of corticosteroids and cyclosporine (cyclosporine dosage can be adjusted); may decrease theophylline levels; inhibition of cytochrome P450 3A4–mediated metabolism of coadministered medications (associated with QT prolongation; therefore, caution with concurrent use of drugs that can prolong the QT interval) Interacts with all medications metabolized via P450 system (primarily CYP 3A4) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
| Precautions | Hepatotoxicity may occur; may reversibly decrease corticosteroid serum levels (adverse effects avoided with dose of 200-400 mg/d); administer antacid, anticholinergics, or H2 blockers at least 2 h after taking oral ketoconazole; if sensitivity or irritation develops with topical formulation, discontinue use; topical form is for external use only; avoid contact with eyes; caution in achlorhydria (reduces absorption); considered unsafe in persons with acute porphyrias (adrenal suppression, gynecomastia, hypocholesterolemia, and hypothyroidism have been cause by the administration of ketoconazole) |
Drug Category: Antiviral agents
Inhibitors of DNA polymerase in HSV-1 and HSV-2 strains, inhibiting viral replication.
| Drug Name | Famciclovir (Famvir) |
| Description | Prodrug that, when biotransformed into active metabolite penciclovir, may inhibit viral DNA synthesis/replication. |
| Adult Dose | 125 mg bid for 5 d |
| Pediatric Dose | Not recommended |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration of probenecid, zidovudine, or cimetidine may increase toxicity; coadministration increases bioavailability of digoxin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
| Precautions | Caution in renal failure or with coadministration of nephrotoxic drugs; thousands of pregnancies are documented in the acyclovir registry and hundreds are in the valacyclovir and famciclovir registries without any reports of increased fetal defects or pregnancy difficulties due to these drugs Caution in glucose-galactose malabsorption or intolerance or severe lactase deficiency (tabs contain lactose); acute renal failure reported |
Further Outpatient Care
Arrange a follow-up visit within 2 weeks to check response to treatment.
Deterrence/Prevention
Avoid shaving irritated skin for 1 month or until all lesions have resolved. To prevent future lesions, avoid close shaving and change disposable razors daily. In addition, periodically soak electric razor heads in 70% alcohol or diluted bleach for 1 hour to eliminate overgrowth of bacteria or fungi. Good personal hygiene, including bathing, hand washing, and keeping nails short and clean, reduces the risk of folliculitis. Wearing loose rather than snug-fitting clothing helps reduce friction. In cases of acute folliculitis, launder towels, washcloths, and sheets frequently and do not share them with other family members. Hot tubs should be cleaned regularly and appropriately chlorinated.
Complications
Persistent and deep folliculitis can result in scarring, sinus tract formation, and permanent hair loss.
Medical/Legal Pitfalls
If a patient does not improve on standard antimicrobial therapy, consider other causes or resistant organisms and perform culture and biopsy as needed. Failure to treat identifiable causes of folliculitis can result in complications.
| Media file 1:
A 22-month-old boy with a staphylococcal folliculitis on the buttocks. The lesions have been excoriated. Diaper occlusion may have been related to onset of the rash. |
 | View Full Size Image | |
Media type: Photo
|
| Media file 2:
A 30-year-old woman with hot tub folliculitis. She had used a hot tub 2 days prior, wearing a bikini-style bathing suit. |
 | View Full Size Image | |
Media type: Photo
|
| Media file 3:
Pseudomonas folliculitis. Courtesy of Hon Pak, MD. |
 | View Full Size Image | |
Media type: Photo
|
| Media file 4:
Superficial folliculitis with neutrophils concentrated in the upper aspect of the follicle |
 | View Full Size Image | |
Media type: Photo
|
| Media file 5:
Perifolliculitis, showing inflammatory cells surrounding the follicle, |
 | View Full Size Image | |
Media type: Photo
|
- Bragg J, Pomeranz MK. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab. Dermatol Online J. 2007;13(1):1. [Medline].
- Roé E, García Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol. Sep 2006;55(3):429-37. [Medline].
- Walsh SR, Johnson RP. Vaccinia Folliculitis After Primary Dryvax Vaccination. Infect Dis Clin Pract. Mar 2007;15(2):132-4.
- Fox GN, Stausmire JM, Mehregan DR. Traction folliculitis: an underreported entity. Cutis. Jan 2007;79(1):26-30. [Medline].
- Nervi SJ, Schwartz RA, Dmochowski M. Eosinophilic pustular folliculitis: a 40 year retrospect. J Am Acad Dermatol. Aug 2006;55(2):285-9. [Medline].
- Eley CD, Gan VN. Picture of the month. Folliculitis, furunculosis, and carbuncles. Arch Pediatr Adolesc Med. Jun 1997;151(6):625-6. [Medline].
- Yu Y, Cheng AS, Wang L, Dunne WM, Bayliss SJ. Hot tub folliculitis or hot hand-foot syndrome caused by Pseudomonas aeruginosa. J Am Acad Dermatol. Oct 2007;57(4):596-600. [Medline].
- Dong H, Duncan LD. Cytologic findings in Demodex folliculitis: a case report and review of the literature. Diagn Cytopathol. Mar 2006;34(3):232-4. [Medline].
- Böer A, Herder N, Winter K, Falk T. Herpes folliculitis: clinical, histopathological, and molecular pathologic observations. Br J Dermatol. Apr 2006;154(4):743-6. [Medline].
- Weinberg JM, Mysliwiec A, Turiansky GW, Redfield R, James WD. Viral folliculitis. Atypical presentations of herpes simplex, herpes zoster, and molluscum contagiosum. Arch Dermatol. Aug 1997;133(8):983-6. [Medline].
- Majors MJ, Berger TG, Blauvelt A, Smith KJ, Turner ML, Cruz PD Jr. HIV-related eosinophilic folliculitis: a panel discussion. Semin Cutan Med Surg. Sep 1997;16(3):219-23. [Medline].
- Weedon D, Strutton G. Skin Pathology. 2nd ed. New York, NY: Churchill Livingstone; 2002:459-66.
- Arenas R, Toussaint S, Isa-Isa R. Kerion and dermatophytic granuloma. Mycological and histopathological findings in 19 children with inflammatory tinea capitis of the scalp. Int J Dermatol. Mar 2006;45(3):215-9. [Medline].
- Arndt KA, Robinson JK, Wintroub BU, LeBoit PE. Dermatology: Cutaneous Medicine and Surgery in Primary Care. Philadelphia, Pa: WB Saunders; 1997.
- Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. Vol 1. St. Louis, Mo: Mosby; 2003:553-66.
- Zancanaro PC, McGirt LY, Mamelak AJ, Nguyen RH, Martins CR. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol. Apr 2006;54(4):581-8. [Medline].
Folliculitis excerpt Article Last Updated: Apr 17, 2008
|